Literature DB >> 24994905

Validation of the classification criteria for cryoglobulinaemic vasculitis.

Luca Quartuccio1, Miriam Isola1, Laura Corazza1, Manuel Ramos-Casals1, Soledad Retamozo1, Gaafar Mohamed Ragab1, Mostafa Naguib Zoheir1, Manal Abdel-Moneim El-Menyawi1, Mohamed Nabil Salem1, Domenico Sansonno1, Gianfranco Ferraccioli1, Elisa Gremese1, Athanasios Tzioufas1, Michael Voulgarelis1, Dimitris Vassilopoulos1, Salvatore Scarpato1, Nicolò Pipitone1, Carlo Salvarani1, Loic Guillevin1, Benjamin Terrier1, Patrice Cacoub1, Davide Filippini1, Francesco Saccardo1, Armando Gabrielli1, Paolo Fraticelli1, Marco Sebastiani1, Matija Tomsic1, Antonio Tavoni1, Cesare Mazzaro1, Pietro Pioltelli1, Norihiro Nishimoto1, Patrizia Scaini1, Anna Linda Zignego1, Clodoveo Ferri1, Giuseppe Monti1, Maurizio Pietrogrande1, Stefano Bombardieri1, Massimo Galli1, Salvatore De Vita1.   

Abstract

OBJECTIVE: The aim of this study was to validate the classification criteria for cryoglobulinaemic vasculitis (CV).
METHODS: Twenty-three centres were involved. New patients with CV (group A) and controls, i.e. subjects with serum cryoglobulins but lacking CV based on the gold standard of clinical judgment (group B) and subjects without cryoglobulins but with clinical features that can be observed in the course of CV (group C), were studied. Positivity of serum cryoglobulins was necessary for CV classification. Sensitivity and specificity of the criteria were calculated by comparing group A vs group B. The group A vs group C comparison was done to demonstrate the possible diagnostic utility of the criteria.
RESULTS: The study included 268 patients in group A, 182 controls in group B and 193 controls in group C (small vessel vasculitis, 51.8%). The questionnaire (at least 2/3 positive answers) showed 89.0% sensitivity and 93.4% specificity; the clinical item (at least 3/4 clinical involvement) showed 75.7% sensitivity and 89.0% specificity and the laboratory item (at least 2/3 laboratory data) showed 80.2% sensitivity and 62.4% specificity. The sensitivity and specificity of the classification criteria (at least 2/3 positive items) were 89.9% and 93.5%, respectively. The comparison of group A with group C demonstrated the clinical utility of the criteria in differentiating CV from CV mimickers.
CONCLUSION: Classification criteria for CV were validated in a second, large, international study confirming good sensitivity and specificity in a complex systemic disease.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  classification; cryoglobulinaemia; hepatitis C; vasculitis

Mesh:

Year:  2014        PMID: 24994905     DOI: 10.1093/rheumatology/keu271

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  18 in total

Review 1.  Rheumatology in Egypt: back to the future.

Authors:  Tamer A Gheita; Nahla N Eesa
Journal:  Rheumatol Int       Date:  2018-11-07       Impact factor: 2.631

Review 2.  HCV Treatments and Their Integration Into Rheumatology.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Curr Rheumatol Rep       Date:  2015-08       Impact factor: 4.592

Review 3.  Vasculitis for the internist: focus on ANCA-associated vasculitis.

Authors:  Benjamin Chaigne; Loïc Guillevin
Journal:  Intern Emerg Med       Date:  2017-06-16       Impact factor: 3.397

4.  Activation-induced cytidine deaminase in B cells of hepatits C virus-related cryoglobulinaemic vasculitis.

Authors:  S Russi; F Dammacco; S Sansonno; F Pavone; D Sansonno
Journal:  Clin Exp Immunol       Date:  2015-09-17       Impact factor: 4.330

Review 5.  [Cryoglobulinemic vasculitis].

Authors:  N Blank; H-M Lorenz
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

6.  Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective.

Authors:  Hussein El-Fishawy; Gamal Saadi; May Hassaballa; Mohamed Hussein; Wahid Doss; Gaafar Ragab; Rashad Barsoum
Journal:  J Adv Res       Date:  2016-03-02       Impact factor: 10.479

7.  A 36-Year-Old Man With Renal Failure, Fever, and Hypocomplementemia.

Authors:  Kimberly DeQuattro; Anatoly Urisman; Mary Margaretten
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-04       Impact factor: 4.794

8.  Efficacy and safety of sofosbuvir-based, interferon-free therapy : The Management of rheumatologic extrahepatic manifestations associated with chronic hepatitis C virus infection.

Authors:  A A Shahin; H S Zayed; M Said; S A Amer
Journal:  Z Rheumatol       Date:  2018-09       Impact factor: 1.530

9.  Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.

Authors:  Valli De Re; Laura Caggiari; Mariangela De Zorzi; Ombretta Repetto; Anna Linda Zignego; Francesco Izzo; Maria Lina Tornesello; Franco Maria Buonaguro; Alessandra Mangia; Domenico Sansonno; Vito Racanelli; Salvatore De Vita; Pietro Pioltelli; Emanuela Vaccher; Massimiliano Berretta; Massimiliano Beretta; Cesare Mazzaro; Massimo Libra; Andrea Gini; Antonella Zucchetto; Renato Cannizzaro; Paolo De Paoli
Journal:  PLoS One       Date:  2015-02-20       Impact factor: 3.240

Review 10.  Vasculitic syndromes in hepatitis C virus: A review.

Authors:  Gaafar Ragab; Mohamed A Hussein
Journal:  J Adv Res       Date:  2016-12-02       Impact factor: 10.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.